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Editorial
Human pluripotent stem cells have the theoretic ability to
differentiate into all the somatic cell types in the human
body, whereas human somatic stem/progenitor/precursor
cells (hSSCs) are multipotent, indicating that their potential
is restricted to a particular germ layer, organ, or tissue of
origin.1-3 Pluripotent human embryonic stem cells (hESCs),
derived from the inner cell mass or epiblast of the human
blastocyst, have both the unconstrained capacity for
long-term stable undifferentiated growth in culture and the
intrinsic potential for differentiation into all the somatic cell
types in the human body, holding tremendous potential for
restoring human tissue and organ function.1-3 These proper-
ties offer pluripotent hESCs as an unlimited source to gener-
ate the diversity of human somatic cell types for regenerative
medicine and as a model system for studying mechanisms
underlying human embryonic development.1-3 Although
human somatic stem/progenitor/precursor cells have tradi-
tionally been isolated directly from such tissue sources of
origin in vivo (primary hSSCs), the field is becoming in-
creasingly adept at deriving multipotent human somatic
stem/progenitor/precursor cells in vitro from pluripotent
cells (secondary hSSCs).2-5 However, not all pluripotent cells
are stem cells. The scientific definition and proof for human
pluripotent stem cells are that they have the intrinsic ability
of both unlimited or long-term self-renewal and unrestricted
differentiation into all the somatic cell types in the human
body. To circumvent the ethical issues surrounding the der-
ivation of hESCs, in the last few years, pluripoten-
cy-inducing factors, most of which are known oncogenes or
toxic cancerogenic chemicals, have been used to artificially
reprogram somatic cells to induced pluripotent stem (iPS)
cells.1-3 Embryo-originated pluripotent hESCs, which display
high levels of expression of Oct-4, SSEA-4, Tra-1-60, and
Tra-1-81, can maintain prolonged normal stable growth or
self-renewal in non-hostile growth environments containing
the essential developmental components that sustain hESC
pluripotency and self-renewal.1-3, 6 However, so far, there is
no evidence that pluripotent cells derived from other sources
harboring adult nuclei by transcription-factor- or
small-molecule-based reprogramming or somatic cell nuclear
transfer, such as iPS cells or pluripotent cells derived from
cloned embryos, can maintain prolonged normal stable
growth or self-renewal.1-3 In addition, some techniques that
those reports used for their analysis of pluripotent sticky
cells, such as FACS designed for sorting non-sticky adult
cells or western blot analysis designed for detecting weakly
expressed molecules that cannot be detected by immunocy-
tochemical analysis of strongly expressed markers, would
give false positive to a heterogeneous population or a colony
of cells where the majority of cells might be negative.2, 3 The
artificially reprogrammed adult cells, such as iPS cells or
pluripotent cells derived from cloned embryos, are charac-
terized by the expression of embryonic markers that are ini-
tially identified in embryonic tumor/cancer cells and form-
ing teratomas in vivo, which shows these reprogrammed
adult cells might be either pluripotent stem cells or pluripo-
tent cancer cells. These reports have not provided the essen-
tial proofs for human pluripotent stem cells, such as evi-
dences for maintaining long-term genomic integrity or sta-
bility and for differentiation into all normal somatic cell
types in the human body.1-3 Although pluripotent, the artifi-
cially reprogrammed adult cells are made from adult cells,
therefore, they carry many negative repressive chromatin
remodeling factors and unerasable genetic imprints of adult
cells that pluripotent hESCs do not have.1-3 In fact, the iPS
cells differ dependent on cell type of origin and display ab-
normal gene silencing of somatic cells, and iPS cell-derived
cells show accelerated senescence.1-3 Unlike the tight-
ly-regulated in vivo biological reprogramming in the human
reproduction process, insertion or transient expression of
foreign oncogenes in adult somatic cells at a
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a non-physiological level tends to induce cancer phenotypes
and malignant transformation of iPS cells, resulting in low
survival rates and genetic-defects of iPS cell-derived fetus.1-3
It is known that somatic cell nuclear transfer and factor- or
small-molecule-based reprogramming are incapable of re-
storing a correct epigenetic pattern of pluripotent hESCs,
which accounts for abnormal gene expression, accelerated
senescence, and immune-rejection following transplantation
of reprogrammed cells.1-3 In view of the growing interest in
the use of human pluripotent stem cells, these major draw-
backs have raised serious concerns about the genomic integ-
rity of artificially reprogrammed adult cells and, thus, have
diminished the utility of reprogramming somatic cells as
viable therapeutic approaches. So far, the pluripotent hESCs
remain as the only genetically-stable human pluripotent
stem cell source with full-developmental potential in deriv-
ing somatic elements for tissue and function restoration.
The pluripotent state of hESCs is associated with the expres-
sion of a unique group of genes, including Oct-4, alkaline
phosphatase, SSEA-4, Tra-1-60, Tra-1-80, though none of
these markers, in isolation, is exclusively expressed by un-
differentiated hESCs.1-3 Rather, their presence as a group is
associated with the undifferentiated state of pluripotent
hESCs. Gene expression analysis has indicated that stem cells
do not seem to have a common core transcription profile
that dictates the undifferentiated self-renewing state of all
stem cell derivatives, known as stemness.3, 4, 7 There exist
overlaps in gene expression between cells of varying lineages
yet a lack of overlap in the gene expression profiles of vari-
ous types or derivations of stem cells, in spite of their appar-
ent phenotypic similarity.3, 4, 7 Recent studies reveal that dis-
cerning the intrinsic plasticity and regenerative potential of
human stem cell populations reside in chromatin modifica-
tions that shape the respective epigenomes of their deriva-
tion routes.3-5, 7
The pluripotency of hESCs that display normal stable expan-
sion is associated with a globally active acetylated chromatin,
as evident by high levels of expression and nuclear localiza-
tion of active chromatin remodeling factors; weak expression
or cytoplasmic localization of repressive chromatin remod-
eling factors that are implicated in transcriptional silencing;
and residual H3 K9 methylation.3-5, 7 This normal
pluripotency of hESCs is characterized by an epigenome
comprised of a globally open conformation of chromatin
remodeled by Oct-4 primed for unrestricted lineage choic-
es.3-5, 7 The wide distribution pattern of Oct-4 is coincident
with sites of active chromatin modification genome-wide,
suggesting that Oct-4 might play an essential role in the in-
terface of chromatin and transcription regulation to maintain
a pluripotent epigenome enabled by a globally active open
chromatin.3-5, 7 The progressive narrowing of potency is asso-
ciated with the gradual restriction in chromatin openness,
hence, lineage choices as a result of global increases in
chromatin-silencing.3-5, 7 The intrinsic plasticity and regen-
erative potential of human stem cell derivatives can be dif-
ferentiated by their epigenomic landscape features.3-5 Human
stem cell derivatives retain more open epigenomic landscape,
therefore, more developmental potential for scale-up regen-
eration, when derived from the pluripotent hESCs in vitro
than from the tissue in vivo.3-5
The openness of pluripotent epigenome differentiates the
active pluripotency of normal hESCs from the repressive
pluripotency of abnormal cells, such as the iPS cells repro-
grammed from adult cells, pluripotent cells derived from
cloned embryos, and pluripotent embryonic carcinoma
cells.3-5, 7 The hESCs are not only pluripotent, but also in-
credibly stable and positive, as evident by that only the posi-
tive active chromatin remodeling factors, but not the nega-
tive repressive chromatin remodeling factors, can be found
in the open epigenome of pluripotent hESCs.3-5, 7 The associ-
ation of pluripotent epigenome of hESCs with a globally
open chromatin state conforms to highly dynamic active
epigenomic remodeling, which provides the molecular
foundation for the normal stable pluripotency of hESCs and
for the genomic integrity of pluripotent stem cells.3-5, 7 Alt-
hough undifferentiated hESCs display the bivalent histone
marks that include the H3K4me3 activation and the
H3K27me3 repressive modifications, only residual
nucleosomal H3 K9 methylation, a chromatin modification
implicated in transcriptional repression during development,
was observed in the open pluripotent epigenome of hESCs.3-5,
7 Residual repressive chromatin remodeling implicated in
chromatin silencing and transcriptional repression might be
essential for stabilizing the pluripotent state of hESCs with a
globally active open epigenome at a normal developmental
stage.3-5, 7 In fact, aberrant H3 K9 methylation at embryonic
stage has been associated with abnormal DNA
hypermethylation and cell malignant transformation in the
pluripotent embryonic carcinoma cells.3
Recent developments in hESC research have overcome some
major obstacles in moving stem cell research from current
studies in animals towards humans for clinical trials, includ-
ing resolving minimal essential human requirements for de
novo derivation and long-term maintenance of clinical-
ly-suitable stable hESC lines and direct conversion of such
pluripotent hESCs into a large supply of clinical-grade func-
tional human neuronal or cardiomyocyte cell therapy prod-
ucts to be translated to patients for CNS or heart repair.1-15
Without an understanding of the essential developmental
components for sustaining pluripotency and self-renewal of
hESCs, hESC lines are at risk for becoming unhealthy and
unstable after prolonged culturing under animal feeders,
feeder-conditioned media, or artificially-formulated chemi-
cally-defined conditions.1-3, 6 Resolving minimal essential
human requirements for sustaining embryonic pluripotency
allows all poorly-characterized and unspecified biological
components and substrates in the culture system, including
those derived from animals, to be removed, substituted, and
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optimized with defined human alternatives for de novo der-
ivation and long-term maintenance of good manufacturing
practice (GMP)-quality xeno-free stable hESC lines and their
human stem cell therapy derivatives.1-3, 6 Formulation of
minimal essential defined conditions renders pluripotent
hESCs be directly and uniformly converted into a specific
neural or cardiac lineage by small signal molecule induc-
tion.1-15 Retinoic acid (RA) was identified as sufficient to
induce the specification of neuroectoderm direct from the
pluripotent state of hESCs maintained under the defined
culture, without going through a multi-lineage embryoid
body (EB) stage, and trigger a cascade of neuronal line-
age-specific progression to human neuronal progenitors
(Xcel-hNuP) and neurons (Xcel-hNu) of the developing CNS
in high efficiency, purity, and neuronal lineage specificity by
promoting nuclear translocation of the neuronal specific
transcription factor Nurr-1.1-5, 9-11 Neuroectoderm specifica-
tion transforms pluripotent hESCs uniformly into a more
neuronal lineage-specific nuclear Nurr1-positive embryonic
neuronal progenitor than the prototypical
neuroepithelial-like nestin-positive human neural stem cells
(hNSCs) derived either from CNS or hESCs.1-5, 9-11 Ge-
nome-scale profiling of microRNA (miRNA) differential
expression showed that the expression of
pluripotency-associated hsa-miR-302 family was silenced
and the expression of Hox miRNA hsa-miR-10 family that
regulates gene expression predominantly in neuroectoderm
was induced to high levels in those hESC-derived neuronal
progenitors.2, 3, 10, 11 Following transplantation, those hESC
neuronal derivatives engrafted widely and yielded
well-dispersed and well-integrated human neurons at a high
prevalence within neurogenic regions of the brain.3, 5, 11 This
technology breakthrough enables well-controlled generation
of a large supply of neuronal lineage-specific progenies
across the spectrum of developmental stages direct from the
pluripotent state of hESCs with small molecule induction,
providing an adequate neurogenic human cell source for
developing safe and effective stem cell therapy for CNS re-
pair in a wide range of neurological disorders.1-5, 9-11
Similarly, nicotinamide (NAM) was identified sufficient to
induce the specification of cardiomesoderm direct from the
pluripotent state of hESCs maintained under the defined
culture, without going through a multi-lineage embryoid
body stage, by promoting the expression of the earliest car-
diac-specific transcription factor Csx/Nkx2.5 and triggering
progression to cardiac precursors (Xcel-hCardP) and beating
cardiomyocytes (Xcel-hCM) with high efficiency.1-3, 6, 8, 12-15
Cells within the beating cardiospheres expressed markers
characteristic of cardiomyocytes and electrical profiles of the
cardiomyocytes confirmed their contractions to be strong
rhythmic impulses reminiscent of the p-QRS-T-complexes
seen from body surface electrodes in clinical electrocardio-
grams.1-3, 6, 8 This novel approach of hESC cardiac line-
age-specific differentiation direct from the pluripotent stage
using small molecule induction is a major milestone towards
human trials of hESC cardiac cell therapy derivatives, offer-
ing the benefits in efficiency, purity, stability, safety, and
scale-up production of clinical-grade hESC cardiac cell ther-
apy products in cGMP facility over all other existing con-
ventional approaches.1-3, 6, 8, 12-15 Currently, these hESC
cardiomyocyte cell therapy derivatives are the only available
human cell sources in large commercial scales with adequate
cellular pharmacologic utility and capacity to regenerate the
contractile heart muscle, vital for heart repair in the clinical
setting.1-3 Nuclear translocation of NAD-dependent histone
deacetylase SIRT1 and global chromatin silencing lead to
hESC cardiac fate determination, while silencing of
pluripotency-associated hsa-miR-302 family and drastic
up-regulation of neuroectodermal Hox miRNA hsa-miR-10
family lead to hESC neural fate determination.2, 3, 10, 11 Em-
bedding lineage-specific genetic and epigenetic programs
into the open epigenomic landscape of pluripotent hESCs
offers a new dimension for direct control and modulation of
the pluripotent fate of hESCs when deriving a large supply of
clinical-grade genetically-stable somatic cell lineages for
regenerative therapies.
References
1. Parsons XH, Teng YD, Moore DA, Snyder EY. Pa-
tents on Technologies of Human Tissue and Organ
Regeneration from Pluripotent Human Embryonic
Stem Cells. Rec Pat Regen Med 2011; 1: 142-163.
2. Parsons XH. Constraining the pluripotent fate of
human embryonic stem cells (hESCs) for tissue en-
gineering and cell therapy - the turning point of
cell-based regenerative medicine. British Biotech J
2013; 3: 424-457.
3. Parsons XH. Embedding the future of regenerative
medicine into the open epigenomic landscape of
pluripotent human embryonic stem cells. Ann Rev
Res Biol 2013; 3: 323-349.
4. Parsons XH. Human Stem Cell Derivatives Retain
More Open Epigenomic Landscape When Derived
from Pluripotent Cells than from Tissues. J Regen
Med 2013; 1: 1000103.
5. Parsons XH. An engraftable human embryonic stem
cell neuronal lineage-specific derivative retains em-
bryonic chromatin plasticity for scale-up CNS re-
generation. J Reg Med & Tissue Eng 2012; 1: 3.
6. Parsons JF, Smotrich DB, Gonzalez R, Snyder EY,
Moore DA, Parsons XH. Defining Conditions for
Sustaining Epiblast Pluripotence Enables Direct In-
duction of Clinically-Suitable Human Myocardial
Grafts from Biologics- Free Human Embryonic Stem
Cells. J Clin Exp Cardiolog 2012; S9-001.
7. Parsons XH. The Dynamics of Global Chromatin
Remodeling are Pivotal for Tracking the Normal
Pluripotency of Human Embryonic Stem Cells. Anat
Physiol 2012; S3:002.
4 Parsons: The openness of pluripotent epigenome International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Parsons ISSN 2330-4049
8. Parsons XH, Teng YD, Parsons JF, Snyder EY,
Smotrich DB, Moore DA. Efficient derivation of
human cardiac precursors and cardiomyocytes from
pluripotent human embryonic stem cells with small
molecule induction. J Vis Exp 2011; 57:e3274.
9. Parsons XH, Teng YD, Parsons JF, Snyder EY,
Smotrich DB, Moore DA. Efficient derivation of
human neuronal progenitors and neurons from plu-
ripotent human embryonic stem cells with small
molecule induction. J Vis Exp 2011; 56:e3273.
10. Parsons XH. MicroRNA profiling reveals distinct
mechanisms governing cardiac and neural line-
age-specification of pluripotent human embryonic
stem cells. J Stem Cell Res Ther 2012; 2:124.
11. Parsons XH, Parsons JF, Moore DA. Genome-scale
mapping of microRNA signatures in human embry-
onic stem cell neurogenesis. Mol Med Ther 2012;
1:105.
12. Parsons XH. Mending the broken heart - Towards
clinical application of human embryonic stem cell
therapy derivatives. J Clin Exp Cardiolog 2012;
3:e116.
13. Parsons XH. Cellular medicine for the heart - the
pharmacologic utility and capacity of human cardiac
stem cells. J Clin Exp Cardiolog 2013; S11-e001.
14. Parsons XH. Exploring future cardiovascular medi-
cine: heart precursors directed from human embry-
onic stem cells for myocardium regeneration.
Cardi
cine for heart reconstitution with efficiency in de-
riving cardiac elements from pluripotent human
embryonic stem cells (Editorial). Cardiol Pharmacol
2013; 2:e112.
ol Pharmacol 2013; 2:e110.
15. Parsons XH. Reviving cell-based regenerative medi-
